|1.||Choi, Dongil: 8 articles (01/2010 - 04/2002)|
|2.||Lee, Won Jae: 7 articles (01/2010 - 04/2002)|
|3.||Kim, Seung Hoon: 7 articles (05/2008 - 04/2002)|
|4.||Frank, Joseph A: 6 articles (04/2011 - 08/2003)|
|5.||Arbab, Ali S: 6 articles (09/2007 - 10/2002)|
|6.||Lim, Jae Hoon: 6 articles (09/2006 - 04/2002)|
|7.||Minamiya, Yoshihiro: 5 articles (08/2015 - 08/2003)|
|8.||Mori, Kensaku: 5 articles (06/2015 - 10/2002)|
|9.||Kim, Joo Hee: 5 articles (07/2011 - 05/2002)|
|10.||Chung, Jae-Joon: 5 articles (07/2011 - 05/2002)|
|1.||Hepatocellular Carcinoma (Hepatoma)
01/01/2009 - "Detection of hepatocellular carcinoma by ferucarbotran-enhanced magnetic resonance imaging: the efficacy of accumulation phase fat-suppressed T1-weighted imaging."
09/01/2007 - "To investigate the diagnostic efficacy of sequentially acquired gadobenete dimeglumine-enhanced 3-dimensional dynamic magnetic resonance imaging (MRI) and Resovist-enhanced MRI for detecting hepatocellular carcinoma (HCC) by comparing with combined computed tomography (CT) hepatic arteriography (CTHA) and CT arterioportography (CTAP) using 16-slice multidetector CT. "
04/01/2005 - "Seventy-three consecutive patients with 121 hepatocellular carcinomas underwent ferucarbotran-enhanced MRI, including a dynamic study, and triple-phase MDCT before hepatic resection. "
02/01/2001 - "The purpose of this study was to compare ferumoxides-enhanced MR imaging with combined helical CT during arterial portography and CT hepatic arteriography for preoperative detection of hepatocellular carcinomas. "
11/01/2013 - "101 hepatocellular carcinomas were treated by RFA after ferucarbotran administration. "
11/01/1995 - "Thus, ENDOREM is useful for preoperative staging of liver tumors due to improvement in lesion detection and delineation of the hepatic vascular system."
05/01/2009 - "The feasibility of magnetic resonance (MR) imaging with impaired clearance of ferucarbotran to visualize ablated liver parenchyma surrounding a tumor (ablative margin [AM]) was evaluated after radiofrequency (RF) ablation of the liver. "
08/01/1995 - "Resovist improved tumor liver contrast and lesion-conspicuity, especially for lesions smaller than 1 cm. The dose of 8 mumol Fe/kg was sufficient to achieve diagnostic tumor-liver contrast. "
10/01/2005 - "This animal study showed that ferucarbotran was useful to detect bone marrow tumors. "
03/01/2000 - "In a clinical study, 10 micromol/kg of ferumoxides was given in 34 consecutive patients with 31 solid tumors. "
|3.||Neoplasm Metastasis (Metastasis)
12/01/1998 - "We conclude that ferumoxides-enhanced MR imaging is superior to unenhanced MR imaging and biphasic spiral CT for depiction of colorectal liver metastases. "
12/01/1998 - "The purpose of this study was to compare the efficacy of unenhanced and ferumoxides-enhanced magnetic resonance imaging with that of dual-phase spiral CT and spiral CT during arterial portography (CTAP) for the detection of colorectal liver metastases. "
09/01/2010 - "To retrospectively evaluate the efficacy of biphasic magnetic resonance imaging (MRI) of the liver with ferucarbotran-enhancement for the characterization of hepatic metastases. "
09/01/2010 - "Characterization of liver metastases: the efficacy of biphasic magnetic resonance imaging with ferucarbotran-enhancement."
11/01/2008 - "Combining ferucarbotran-enhanced T2*W-GRE and T2W-TSE has additive efficacy for detecting HCC in cirrhotic patients, but T2W-TSE is preferred for detecting metastases in non-cirrhotic patients."
10/01/2002 - "Ferumoxides-enhanced gradient-echo sequences improved the diagnostic accuracy and the sensitivity for detecting malignant hepatic lesions in patients with end-stage cirrhosis of the liver. "
09/01/1999 - "The dose-dependency and rate of decay of efficacy of Resovist in cirrhosis were similar to those in normal liver, although the efficacy was less in cirrhotic liver and both the dose-dependency and rate of decay of efficacy were dependent on imaging parameters."
03/01/2001 - "We describe ferumoxides-enhanced magnetic resonance imaging findings in a 60-year-old man with confluent hepatic fibrosis in advanced cirrhosis. "
03/01/2001 - "Confluent hepatic fibrosis in cirrhosis: ferumoxides-enhanced MR imaging findings."
09/01/2003 - "Forty-two liver transplant candidates with end-stage cirrhosis underwent SPIO-enhanced MRI at 1.5T, using either 15 micromol/kg or 7.5 micromol/kg ferumoxides. "
|5.||Liver Cirrhosis (Hepatic Cirrhosis)
07/01/2012 - "Capturing the signal dynamics during bolus injection of ferucarbotran in DC-MRI of the liver allows for semiquantitative assessment of hepatic perfusion that may be helpful for a more precise characterisation of liver cirrhosis and focal liver lesions."
09/01/2003 - "The aim of this study was to establish whether enhancement of the liver by the MRI contrast agent ferumoxides could be effectively achieved at a reduced dose of 7.5 micromol/kg in patients with advanced liver cirrhosis. "
01/01/2000 - "The goal of this study was compare the effect of Endorem on the signal intensity of the spleen in patients with normal liver tissue and in patients with liver cirrhosis. "
07/01/2012 - "In total 31 patients (21 men; 58 ± 10 years) including 18 patients with biopsy proven liver cirrhosis prospectively underwent clinically indicated DC-MRI at 1.5 Tesla (T) with dynamic T2-weighted gradient-echo imaging after ferucarbotran bolus injection. "
05/01/2002 - "Effect of resovist on rats with different severities of liver cirrhosis."
|2.||ferric oxide (iron oxide)
|3.||Gadolinium DTPA (Magnevist)
|4.||N,N'- bis(pyridoxal- 5- phosphate)ethylenediamine- N,N'- diacetic acid (mangafodipir)
|8.||Protamines (Protamine Sulfate)
|1.||Drug Therapy (Chemotherapy)
|2.||Lymph Node Excision (Lymph Node Dissection)
|3.||Heterologous Transplantation (Xenotransplantation)
|4.||Transplantation (Transplant Recipients)